VAMDRUP, Denmark, February 3rd, 2022 – Impilo and SHS have acquired Lowenco A/S (“Lowenco” or the “Company”) from its founder and owners. Lowenco was founded 2013 in Vamdrup, Denmark, and develops, manufactures, markets, and installs large scale modular and highly energy efficient ultra-low temperature (“ULT”) storage solutions for commercial biopharma, primarily targeting the drug substance […]

In January 2021, SHS sold its shares in the Austrian life science supplier Single Use Support GmbH (SUS). The patent-protected liquid logistics system developed by SUS is considered the gold standard today. Among other things, SHS established a scalable corporate organisation at SUS and optimised the supply chains. During the investment phase, SUS multiplied its […]

evitria AG from Switzerland is one of the leading life science companies for specific antibodies. Customers working with evitria products include global pharmaceutical companies as well as academic laboratories and biotech companies around the world. SHS invested from the SHS V fund in 2018. The highly successful exit for SHS investors took place in summer […]

phenox GmbH from Bochum is an extremely innovative, fast-growing medtech company whose products for minimally invasive intervention help prevent or reduce the consequences of a stroke every day. SHS supports the company with growth capital and know-how as it enters new markets.

Private equity: high-yield investment as part of diversification In turbulent times like these, when a lot of money is looking for attractive investment opportunities, private equity is more popular than ever as an investment form among institutional investors. Even in 2020, when the world was hit by the Corona pandemic, there were more than 8000 […]

SHS has been an official member of the United Nations Initiative for Responsible Investment, or UN PRI, since September 2021. What does UN PRI membership mean for SHS? Dr André Zimmermann (Partner and Head of ESG at SHS): As a specialised healthcare investor, SHS has been investing according to ethical standards for more than 25 […]

An interview with Dr Hanno Kühn, Chief Investment Officer (CIO) and head of apoBank’s institutional investment business, and Hubertus Leonhardt, Managing Director and partner of SHS Gesellschaft für Beteiligungsmanagement mbH. Düsseldorf and Tübingen , 22.7.2021 As the largest cooperative primary bank in Germany, apoBank is the number one financial services provider in the health care […]

As an important future and economic factor, the healthcare industry has become more visible to the public in the past 20 months. There has also been significant movement in the market for healthcare investments. In the first half of 2021, the volume of M&A activities in the DACH region increased by around 20 % compared […]

Medical technology market in Germany to remain at a high level in 2020, but with slight declines Pandemic leaves both positive and negative traces on medical technology companies SHS expects better development for medical technology than for the overall economy in Germany in 2021 despite Corona The new regulatory requirements (MDR) continue to burden many […]

The renowned Hertie-Institut Tübingen together with the Neurological Clinic of the Universitätsklinikum Tübingen form the “Centre for Neurology”. The centre was created with the contract signed in 2001 between the Gemeinnützige Hertie-Stiftung and the state of Baden-Württemberg, the Universität Tübingen and its medical faculty, and the Universitätsklinikum Tübingen. This interaction of public resources and private […]

In the car industry in particular, a robot-controlled production process already seems normal to us. But in medicine? Let’s take a look into the operating theatre of a urological centre in Germany in 2021!

Large investors often expect double-digit returns from private equity investments. Would this also be achievable for private investors? Risks and peculiarities should be very well known.